In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Epizyme (NASDAQ: EPZM), with a price target of $25. The company’s shares opened today at $13.80.
Cann wrote:
“Our financial outlook for 2018-2022 remains basically unchanged. Clinical programs are on-track as of the most recent update. We continue to anticipate phase II data for tazemetostat for multiple cancer types through the rest of this year.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 9.1% and a 47.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.13, representing a 74.9% upside.
In a report issued on April 23, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Epizyme’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $36.17 million. In comparison, last year the company had a GAAP net loss of $32.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
